Latest NYSE Euronext Stories

PARSIPPANY, N.J., July 17, 2012 /PRNewswire/ -- DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM N.V. (NYSE, Euronext: DSM KON), announced today that it has signed a biologics contract manufacturing agreement with its first Brazilian client, RECEPTA Biopharma in Sao Paulo. The contract covers the process development and cGMP manufacture by DSM of one of RECEPTA's lead antibodies at its facilities based in Groningen, The Netherlands. DSM...

AMSTERDAM, July 13, 2012 /PRNewswire/ -- Amsterdam Molecular Therapeutics (AMT) Holding NV (in liquidation) (Euronext: AMT) published its Annual Report and Accounts for the year ended December 31, 2011 and announced that it will host its Annual General Meeting at its headquarters (Meibergdreef 61, 1105 BA Amsterdam Zuidoost, the Netherlands) at 14.00 hrs on September 12, 2012. Shareholders of the dissolved company are invited to attend. For further details, agenda and...

LEUVEN, Belgium, July 12, 2012 /PRNewswire/ -- ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces that it has received a transparency declaration from Fidelity Management & Research Company LLC in accordance with the Belgian Law of 2 May 2007 concerning disclosure of major holdings in issuers whose shares are admitted to trading on a Belgian regulated market. ThromboGenics NV...

BELLEVUE, Wash., June 28, 2012 /PRNewswire/ -- Radiant Logistics, Inc. (NYSE MKT: RLGT), a domestic and international transportation and logistics services company, is pleased to announce that it will ring The Opening Bell at the New York Stock Exchange (NYSE) on Friday, July 6th, 2012, to commemorate the Company's recent listing on the NYSE MKT. Radiant's common stock began trading on the NYSE exchange on January 11th, 2012 and was also recently added to the Russell Microcap...

PARSIPPANY, N.J., June 19, 2012 /PRNewswire/ -- DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM N.V. (NYSE, Euronext: DSM KON), announced today that several countries have granted patents or have given statements of patent allowance to its proprietary XD® high cell density process technology. DSM Biologics focuses on optimizing biopharmaceutical manufacturing through its unique set of technologies. The XD® technology is an important...

PARSIPPANY, N.J., June 18, 2012 /PRNewswire/ -- DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM N.V. (NYSE, Euronext: DSM KON), announced today that it has signed a commercial agreement for contract manufacturing services using its proprietary XD® high cell density process technology with a major pharma company. Karen King, President of DSM Biologics, commented "We are proud to announce that a major pharma company has chosen DSM's services...

NIEUWEGEIN, The Netherlands, June 7, 2012 /PRNewswire/ -- The Dutch Public Prosecutor's Office and the Fiscal Information and Investigation Service (FIOD) are conducting a criminal investigation against Ballast Nedam as a suspect related to payments to foreign agents in the period of 1996 - 2004. Ballast Nedam has brought this matter to the attention of the Public Prosecutor's Office in January 2011. As stated in the press release of 21 January 2011 Ballast Nedam...

AMSTERDAM, May 7, 2012 /PRNewswire/ -- Core Laboratories N.V. (trading symbol: "CLB") has received approval from the Netherlands Authority for the Financial Markets ("AFM") for its prospectus to dual-list its shares on NYSE Euronext in Amsterdam ("NYSE Euronext Amsterdam"). In connection with this dual-listing, Core Lab will not be issuing any new shares. The listing on NYSE Euronext Amsterdam will be effective on the morning of Wednesday, 16 May 2012, under the symbol "CLB" and Core...

EXTON, Pa., May 3, 2012 /PRNewswire/ -- Kensey Nash Corporation (Nasdaq: KNSY), today announced that it has entered into a definitive agreement with Royal DSM (DSM) (NYSE Euronext: DSM KON), under which DSM has agreed to acquire all of the common stock of Kensey Nash through a cash tender offer, followed by a merger with a subsidiary of DSM, for $38.50 per share in cash. "We are very pleased to have entered into the merger agreement with DSM, as the transaction will deliver...

CHICAGO, April 30, 2012 /PRNewswire/ -- Zacks.com releases the list of companies likely to issue earnings surprises. This week's list includes Humana (NYSE: HUM), NYSE Euronext (NYSE: NYX), Loews Corp. (NYSE: L), Pfizer (NYSE: PFE) and Archer Daniels Midland (NYSE: ADM). To see more earnings analysis, visit http://at.zacks.com/?id=3207. (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Every day, Zacks.com makes 4 stock picks available, free of charge. To see them, go to...